Business Context and Reporting Period
Company: Altimmune, Inc. (ALT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Altimmune is a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases. Its lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for MASH, Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD). The company has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Revenues | $5 | $5 | $10 | $10 |
| Net Loss | $(22,146) | $(24,640) | $(41,721) | $(49,034) |
| Diluted EPS | $(0.27) | $(0.35) | $(0.53) | $(0.69) |
| Operating Expenses | $22,927 | $26,750 | $44,747 | $53,549 |
| Cash & Equivalents (End of Period) | $183,105 | $57,169 | $183,105 | $57,169 |
| Total Debt (Term Loan) | $14,332 | $0 | $14,332 | $0 |
| Accumulated Deficit | $(603,111) | $(515,365) | $(603,111) | $(515,365) |
Material Changes vs. Prior Period
- Revenue: Remained negligible at $5,000 for the quarter and $10,000 for the six months, consistent with the prior year.
- Net Loss: Improved by 10% in Q2 and 15% in the six-month period compared to 2024, driven primarily by reduced R&D expenses.
- R&D Expenses: Decreased by 19% in Q2 and 22% in the six-month period. This reduction was due to lower MASH trial enrollment costs and the termination of the HepTcell program in 2024, partially offset by new costs for AUD and ALD trials.
- Liquidity: Cash and cash equivalents increased significantly from $36.9 million at year-end 2024 to $183.1 million at June 30, 2025. This was driven by $72.6 million in net proceeds from at-the-market (ATM) equity offerings and $15.0 million from a new term loan.
- Debt: The company entered a new $100 million term loan facility with Hercules Capital, Inc. in May 2025, drawing the first tranche of $15.0 million. The effective interest rate is 14.4%.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- MASH: Released topline results from the IMPACT Phase 2b trial showing statistically significant MASH resolution (59.1% and 52.1% for 1.2mg and 1.8mg doses vs. 19.1% placebo) and weight loss.
- AUD & ALD: Initiated Phase 2 trials (RECLAIM for AUD and RESTORE for ALD) with first patient enrollment announced in May and July 2025, respectively.
- Liquidity Outlook: Management believes current cash resources ($183.1 million) plus expected R&D incentives are sufficient to fund operations for at least 12 months from the filing date.
- Capital Strategy: The company continues to utilize its ATM offering programs. As of June 30, 2025, $106.2 million remained available under the 2025 ATM agreement. Subsequent to the period end, an additional $12.8 million was raised in July 2025.
- Risks & Contingencies:
- Litigation: A new class action lawsuit (Collier v. Altimmune, Inc.) was filed in August 2025 alleging false statements regarding pemvidutide and the IMPACT trial. A previous derivative action was dismissed without prejudice in February 2025.
- Debt Covenants: The new term loan includes financial covenants, though compliance is conditionally waived if market capitalization exceeds $800 million.
- Regulatory: The company is assessing the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 but does not expect a material impact on the 2025 effective tax rate.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $183.1 million cash balance against the burn rate of ~$36 million per six months in operating cash flow.
- Debt Terms: Review the specific milestones required to unlock the remaining $85 million of the Hercules Capital term loan and the implications of the 14.4% effective interest rate.
- ATM Capacity: Monitor the remaining $106.2 million capacity under the 2025 ATM agreement and the potential for further dilution.
- Litigation Exposure: Assess the potential financial and reputational impact of the August 2025 class action lawsuit regarding the IMPACT trial data.
- Clinical Milestones: Track enrollment and data readouts for the new AUD (RECLAIM) and ALD (RESTORE) Phase 2 trials to validate the expansion of the pemvidutide pipeline.